BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 3917257)

  • 1. Reversal of diabetic cataract by sorbinil, an aldose reductase inhibitor.
    Beyer-Mears A; Cruz E
    Diabetes; 1985 Jan; 34(1):15-21. PubMed ID: 3917257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of stage-I sugar cataract by Sorbinil, an aldose reductase inhibitor.
    Beyer-Mears A; Cruz E; Varagiannis E
    Pharmacology; 1985; 31(2):88-96. PubMed ID: 3927328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonosmotic diabetic cataracts.
    Malone JI; Lowitt S; Cook WR
    Pediatr Res; 1990 Mar; 27(3):293-6. PubMed ID: 2138728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the aldose reductase inhibitor sorbinil on the isolated cultured rat lens.
    Yeh LA; Rafford CE; Beyer TA; Hutson NJ
    Metabolism; 1986 Apr; 35(4 Suppl 1):4-9. PubMed ID: 3083208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Raman spectroscopic study of the effect of aldose reductase inhibitor on experimental diabetic cataract.
    Nozawa H; Yaginuma T; Mizuno A
    Nippon Ganka Gakkai Zasshi; 1988 Jan; 92(1):194-201. PubMed ID: 3133929
    [No Abstract]   [Full Text] [Related]  

  • 6. Cataract prevention in diabetic Octodon degus with Pfizer's sorbinil.
    Datiles MB; Fukui H
    Curr Eye Res; 1989 Mar; 8(3):233-7. PubMed ID: 2523284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergism of sorbinil and normal diet on reversal of stage-II sugar cataract.
    Beyer-Mears A; Kelly K; Cruz E
    Pharmacology; 1985; 31(3):170-9. PubMed ID: 3931105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of aldose reductase inhibitor sorbinil on neuroaxonal dystrophy and levels of myo-inositol and sorbitol in sympathetic autonomic ganglia of streptozocin-induced diabetic rats.
    Schmidt RE; Plurad SB; Sherman WR; Williamson JR; Tilton RG
    Diabetes; 1989 May; 38(5):569-79. PubMed ID: 2497038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorbinil protection of lens protein components and cell hydration during diabetic cataract formation.
    Beyer-Mears A; Cruz E; Nicolas-Alexandre J; Varagiannis E
    Pharmacology; 1982; 24(3):193-200. PubMed ID: 6803262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Na+-K+-ATPase pumping activity is not directly linked to myo-inositol levels after sorbinil treatment in lenses of diabetic rats.
    Yeh LA; Rafford CE; Goddu KJ; Ashton MA; Beyer TA; Hutson NJ
    Diabetes; 1987 Dec; 36(12):1414-9. PubMed ID: 2824260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-performance liquid chromatographic analysis of glucose, fructose, sorbitol and low levels of the aldose reductase inhibitor sorbinil in human lens and plasma.
    Lloyd P; Crabbe MJ
    J Chromatogr; 1985 Oct; 343(2):402-6. PubMed ID: 3934205
    [No Abstract]   [Full Text] [Related]  

  • 12. The effect of aldose reductase and its inhibition on sugar cataract formation.
    Kador PF; Akagi Y; Kinoshita JH
    Metabolism; 1986 Apr; 35(4 Suppl 1):15-9. PubMed ID: 3083204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of M79175, an aldose reductase inhibitor, on experimental sugar cataracts].
    Ono H; Nozawa Y; Hayano S
    Nippon Ganka Gakkai Zasshi; 1982; 86(9):1343-50. PubMed ID: 6818854
    [No Abstract]   [Full Text] [Related]  

  • 14. Myo-inositol and sorbitol metabolism in relation to peripheral nerve function in experimental diabetes in the rat: the effect of aldose reductase inhibition.
    Gillon KR; Hawthorne JN; Tomlinson DR
    Diabetologia; 1983 Oct; 25(4):365-71. PubMed ID: 6416913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diabetic complications in lens and nerve and their prevention by sulindac or sorbinil: two novel aldose reductase inhibitors.
    Jacobson M; Sharma YR; Cotlier E; Hollander JD
    Invest Ophthalmol Vis Sci; 1983 Oct; 24(10):1426-9. PubMed ID: 6413448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of an aldose reductase inhibitor (Sorbinil) on the level of metabolites in lenses of diabetic rats.
    Gonzalez AM; Sochor M; McLean P
    Diabetes; 1983 May; 32(5):482-5. PubMed ID: 6404681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A study of the limitations of ARI treatment of streptozotocin-induced diabetic cataracts].
    Kojima M; Sasaki K
    Nippon Ganka Gakkai Zasshi; 1986 Dec; 90(12):1669-73. PubMed ID: 2950739
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment with aldose reductase inhibitor or with myo-inositol arrests deterioration of the electroretinogram of diabetic rats.
    MacGregor LC; Matschinsky FM
    J Clin Invest; 1985 Aug; 76(2):887-9. PubMed ID: 3928685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prevention of rat galactose cataract with topical aldose reductase inhibitor, E-1008].
    Tasaka H; Akagi Y; Yoshikawa T; Ikebe H; Takahashi Y; Chamoto K; Miyamoto Y; Terubayashi H
    Nippon Ganka Gakkai Zasshi; 1987 Feb; 91(2):246-53. PubMed ID: 3111200
    [No Abstract]   [Full Text] [Related]  

  • 20. Altering the course of cataracts in diabetic rats.
    Fukushi S; Merola LO; Kinoshita JH
    Invest Ophthalmol Vis Sci; 1980 Mar; 19(3):313-5. PubMed ID: 6766909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.